Last reviewed · How we verify
enoxaparin + clopidogrel + aspirin
This combination uses enoxaparin (anticoagulant), clopidogrel (antiplatelet), and aspirin (antiplatelet) to prevent thrombotic events through multiple pathways of coagulation and platelet inhibition.
This combination uses enoxaparin (anticoagulant), clopidogrel (antiplatelet), and aspirin (antiplatelet) to prevent thrombotic events through multiple pathways of coagulation and platelet inhibition. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Thromboembolism prevention in high-risk cardiovascular patients.
At a glance
| Generic name | enoxaparin + clopidogrel + aspirin |
|---|---|
| Also known as | Lovenox Plavix Kardégic |
| Sponsor | Centre Hospitalier de PAU |
| Drug class | Anticoagulant + antiplatelet combination |
| Target | Factor Xa, Factor IIa, P2Y12 receptor, cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin is a low-molecular-weight heparin that inhibits factors Xa and IIa in the coagulation cascade. Clopidogrel and aspirin are antiplatelet agents that work synergistically—clopidogrel inhibits ADP-mediated platelet activation via P2Y12 receptor antagonism, while aspirin irreversibly inhibits cyclooxygenase and thromboxane A2 production. Together, this triple therapy provides comprehensive antithrombotic coverage.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Thromboembolism prevention in high-risk cardiovascular patients
Common side effects
- Bleeding/hemorrhage
- Thrombocytopenia
- Injection site reactions (enoxaparin)
- Dyspepsia
- Anemia
Key clinical trials
- Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI (PHASE3)
- The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI (PHASE4)
- Anticoagulant Treatments and Percutaneous Coronary Angioplasty (PHASE4)
- Acute Coronary Syndrome Sri Lanka Audit Project
- The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis. (NA)
- The Safety of Hand Surgery in the Anticoagulated Patient
- To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection (PHASE3)
- Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- enoxaparin + clopidogrel + aspirin CI brief — competitive landscape report
- enoxaparin + clopidogrel + aspirin updates RSS · CI watch RSS
- Centre Hospitalier de PAU portfolio CI